Clinical Trials
3 trialsNCT04182204 2025-12-22
POLARGO
Hoffmann-La Roche
Phase 3 Completed
NCT02257567 2022-11-14
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 1/2 Completed
NCT02729896 2020-12-23
A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
Phase 1/2 Completed